Tribunal approves Dr. Smiths Biotech resolution plan; Cian loses subsidiary
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts more than Nifty Microcap 250 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The National Company Law Tribunal approved Ananta Medicare's plan for Dr. Smiths Biotech, Cian's wholly owned subsidiary in an insolvency process. On October 23, 2026, its equity was cancelled, it ceased to be a subsidiary, and no payment was received. The creditor claim was Rs 8.55 crore, with Rs 8.47 crore admitted.
Cian exits a loss-making subsidiary with negative net worth. No cash proceeds were received; the final effect on profit or net worth is not stated.